Huma Therapeutics has announced the completion of its latest funding round with financing of approximately US$130 million. The investment will scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology and Innovation Fund by HAT, as well as individuals, Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
A further commitment of US$70 million that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than US$200 million.
Click below to share this article